Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.
about
From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsGlutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinomaDAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumorsConditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma.Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix.RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent mannerIdentification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis.Introduction: The Changing Directions of p53 Research.WIP1 stimulates migration and invasion of salivary adenoid cystic carcinoma by inducing MMP-9 and VEGF-C.Regulation of the Wip1 phosphatase and its effects on the stress response.Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancerp53 and p16Ink4a/p19Arf Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor CellsSexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5.Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesisLIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway.The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.Pancreatic neuroendocrine tumors: a comprehensive review.Profiling mTOR pathway in neuroendocrine tumors.Zollinger-Ellison syndrome: recent advances and controversies.Wip1 phosphatase in breast cancer.Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.Netrin-1 promoted pancreatic cancer cell proliferation by upregulation of Mdm2.Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin.Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells.PPM1D is a prognostic marker and therapeutic target in colorectal cancerTargeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodenroglial Tumors.Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors.The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.New Epigenetic Drivers of CancersProfiling of GEPNETs
P2860
Q26822011-AE8C09FD-C21E-4CA8-AC3D-F2A19140A447Q28239503-FAF726AA-1FE9-4F12-B688-24D5D1007F1EQ28303693-29E21D06-4513-43AF-8846-CA87AB132A47Q33700895-BA29C688-A5A7-4C6C-9E0D-CDBCF975BDEEQ34271356-0D0559B3-970D-401F-8757-E9042DDF8807Q34518263-9E791EDE-3C77-4119-8E7E-709924077921Q34731699-0BC48609-0062-4832-A53C-F7F2960C3B40Q35103185-16165613-DECC-44EB-B3A2-27F662B93868Q35832298-052C464F-6022-41AF-8FA4-43FF14CEBBAAQ36429982-5BA125FE-3FBF-4472-A3A2-19D2D42A45B6Q36741571-03089B77-7917-4F49-8F72-1B7DB05BF70BQ37280291-66412B49-107D-4AA9-8C89-CFA9D5BE7519Q37327558-7DE1FF6E-8D08-4369-982F-7C4A810F45F3Q37634917-5F50C248-28A2-4994-8AF5-C6D6C763B56AQ37650965-4C335725-C3D6-4913-A694-A2F9793E9292Q37718451-34AF4CC2-98FA-43A4-971D-64FCF871020FQ37832970-B6C42D92-9D82-41DC-B6BC-EE4B35CFF514Q37995947-E9525559-426C-44DD-9D87-D66E9A279384Q38034440-50AC6A90-8FE3-4C55-9ED4-E5C603922FC3Q38150165-C2C8D741-5938-4452-8354-503FE3279208Q38266298-9358BC50-0586-49CD-B9A0-F1937F8BE66BQ38952182-CC3DDF69-C6C0-48FB-B686-836EE79162AAQ38977447-5D62AC4A-2082-4019-BBC5-CA353F47EB0EQ40379442-6667B15A-28E9-41D9-BFAD-40BC5357F69BQ41145151-2120AD9F-FFE3-4E83-84A0-F69B66AEEE04Q42718225-0058AE6A-1AB6-4274-94D2-FE34DD3D5AB1Q47393972-E066C55E-95FB-46E2-8606-44FF4C135A52Q47631527-2763DA94-4AA3-4D6B-BC2E-ECE28FED2E8DQ51019130-AAEF63BF-C3A1-468F-9F05-9157D135A493Q55260441-28E06DEE-51FC-4B3D-BDB9-A3C3DBEF2354Q56929412-B2746678-15FA-4136-8D62-E96A05A595ACQ58693024-A625AB9D-2B23-41B7-90A6-B553C895BC38
P2860
Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@ast
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@en
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@nl
type
label
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@ast
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@en
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@nl
prefLabel
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@ast
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@en
Gene Amplifications in Well-Di ...... rs Inactivate the p53 Pathway.
@nl
P2093
P2860
P50
P356
P1433
P1476
Gene Amplifications in Well-Di ...... ors Inactivate the p53 Pathway
@en
P2093
David S Klimstra
Ippolito Modica
Laura H Tang
Peter J Allen
Zhaohui Feng
P2860
P304
P356
10.1177/1947601910371979
P577
2010-05-01T00:00:00Z